A Study of Continuous Blood Pressure Monitoring in Healthy Participants

• Status: Not yet recruiting
• Trial end date: 2023-03-03
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study in healthy participants is to find out whether the traditional ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The study will last about 29 days excluding the screening period of 28 days.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Ephedrine; Propranolol; Pseudoephedrine

Criteria

Inclusion Criteria:

• Are overtly healthy males or females

• Have a body mass index (BMI) of 18.0 to 35 kilograms/square meter (kg/m2), inclusive at screening

• Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study

• Have given written informed consent approved by Lilly and the ethical review board governing the site

Exclusion Criteria:

• Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study

• Have history of sensitive skin or chronic skin conditions, like eczema

• Regular use of known drugs of abuse

• Are women who are pregnant or lactating

• Have known allergies to medications used in the study